Biogen – Rallies 60%

Biogen Inc. – Common is a current holding in our US high conviction portfolio.

The stock price rallied following the FDA decision, which was announced earlier this week, to approve Biogen’s drug Aducanumab, a treatment for Alzheimer’s disease.

You’re not a member!  Trial today

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.